Unveiling Pharmacokinetics and Drug Interaction of Linagliptin and Pioglitazone HCl in Rat Plasma Using LC-MS/MS

• Published in: Chemical research in toxicology 2024-05, Vol.37 (5), p.779-790
• Main Authors: Aref, Heba, Hammad, Sherin, Darwish, Khaled M., Elgawish, Mohamed S.
• Format: Article
• Language: English
• Subjects: Animals; Chromatography, High Pressure Liquid; Drug Interactions; Hypoglycemic Agents - blood; Hypoglycemic Agents - chemistry; Hypoglycemic Agents - pharmacokinetics; Linagliptin - blood; Linagliptin - chemistry; Linagliptin - pharmacokinetics; Liquid Chromatography-Mass Spectrometry; Male; Molecular Structure; Pioglitazone - blood; Pioglitazone - chemistry; Pioglitazone - pharmacokinetics; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry
• ISSN: 0893-228X; 1520-5010
• DOI: 10.1021/acs.chemrestox.4c00038

The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III clinical trials for diabetes mellitus treatment, demonstrated significant improvements in glycemic control. However, the absence of an analytical method for simultaneous determination in biological fluids highlights a crucial gap. This underscores the pressing need for sensitive bioanalytical methods, emphasizing the paramount importance of developing such tools to advance diabetes management strategies and enhance patient care. Herein, a sensitive reverse-phase high-performance liquid chromatography–electrospray ionization-tandem mass spectrometry method was developed for simultaneous determination of LIN and PIO in rat plasma using alogliptin as an internal standard. Chromatographic separation was performed on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using an isocratic mobile phase system consisting of ammonium formate (pH 4.5) and methanol using an acetonitrile-induced protein precipitation technique for sample preparation. Multiple reaction monitoring in positive ion mode was used for quantitation of the precursor to production at m/z 473.2 → 419.9 for LIN, 357.1 → 134.2 for PIO, and 340.3 → 116.1 for ALO. The linearity range was 0.5 to 100 and 1 to 2000 ng/mL for LIN and PIO, respectively. The developed method was validated as per US-FDA guidelines and successfully applied to clinical pharmacokinetic and drug–drug interaction studies with a single oral administration of LIN and PIO in rat plasma. Pharmacokinetic parameters of LIN were significantly influenced by the concomitant administration of PIO and vice versa. Molecular modeling revealed the significant interaction of LIN and PIO with P-glycoprotein. Therefore, the drug–drug interaction between LIN and PIO deserves further study to improve drug therapy and prevent dangerous adverse effects.